Psychedelic medications are a rapidly advancing field, being the first to incorporate the medical and mental health space. This form of medication is one of unique properties maximizing the skillset for practitioners’ medication delivery techniques, as well as therapeutic communication styles. Recognizing this medication class is displaying unprecedented results in allowing improvement in mental health conditions, pain syndromes, and neurodegenerative diseases, the education and skillset possessed by CRNAs allows us to be the leading professionals as no other profession possess such dynamic education and skills. CRNAs should understand the impact their profession can potentially have on this space, and should be able to speak on the medical, business, and political aspects as this could be one of the biggest growths sectors the nursing anesthesia practice has ever seen.
Class A credit can only be earned for participation in synchronous learning via live in-person or live webinar sessions. In-person attendees can only receive Class A credit for the sessions they attend live.
Due to CE guidelines, sessions which are recorded will not be available for viewing immediately following Congress.
Learning Objectives:
Identify psychedelic medicines with noted dates of legal approval from both federal and state requirements.
Understand the pharmacologic nature of psychedelic medications and the application for mental health, pain syndromes, and neurologic disorders.
Understand general concepts for working in the outpatient community and the general needs as a practitioner to meet state and federal guidelines.
